Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
Completed · Phase 3 · NCT04101721
Conditions: Retinopathy of Prematurity
At a glance
- Research payments reported, 2025
- $2,750
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 127
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- aflibercept (drug), laser photocoagulation (procedure)
- Dates
- Started 2019-10-30; completion 2022-08-18
- Results posted
- Yes
The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study are to assess the need for a second treatment modality, to assess the recurrence of ROP in the study and to assess the safety and tolerability of aflibercept.
From ClinicalTrials.gov, last updated 2023-07-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2,750 in research payments for this study in 2025 (1 payments).
Products named: Eylea
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.